CagriSema is an investigational once-weekly injectable that combines cagrilintide 2.4 mg with semaglutide 2.4 mg, and two post hoc analyses of the phase 3 REDEFINE 1 trial now report that women receiving the combination lost a mean 25.0% of body weight at 68 weeks. The analyses were presented at The Menopause Society 2026 Annual Meeting in San Diego, California, and arrive while Novo Nordisk’s New Drug Application for weight management is under FDA review, with a decision expected in the fourth quarter of 2026. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
The numbers matter to the peptide therapy and research peptide industry because they describe, in the largest women-only cut of a dual-incretin dataset to date, what a next-generation peptide combination can do under trial conditions — and how much of that effect survives the difference between an efficacy estimand and a treatment-policy estimand. For clinics, telehealth operators and compounding stakeholders already fielding GLP-1 demand, the gap between 25.0% and the primary publication’s 20.4% is not a rounding error; it is the difference between a controlled trial’s per-protocol effect and a real-world expectation.
What happened in the REDEFINE 1 post hoc analyses
REDEFINE 1 (NCT05567796) was a 68-week, double-blind trial with both placebo and active comparators. It randomly assigned 3417 adults without diabetes — with a BMI of 30 or higher, or 27 or higher plus at least one obesity-related complication — to once-weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg, semaglutide alone, cagrilintide alone, or placebo, with lifestyle intervention in all arms. Women made up approximately two-thirds of participants, according to the trial report.
The first post hoc analysis covered all 2309 women enrolled. Mean weight reduction at week 68 was 25.0% with CagriSema, 19.0% with semaglutide alone, 13.4% with cagrilintide alone and 3.0% with placebo. Waist circumference fell 20.5 cm with the combination versus 4.7 cm with placebo, and 93.3% of women on CagriSema lost at least 10% of body weight while 68.7% lost at least 20%, against 12.7% and 1.8% respectively with placebo.
The second analysis grouped 1902 women on CagriSema or placebo by menopause status. Mean loss was 26.7% versus 2.1% in premenopausal women, 24.8% versus 1.7% in perimenopausal women, and 23.1% versus 2.6% in postmenopausal women. Investigators assigned menopause status after the fact using age, medical history and recorded symptoms; the classification was not based on reproductive staging collected during the trial or on biochemical confirmation. A hormone-therapy subgroup was evaluated separately, but the company release did not report results for that group.
The key numbers, and the caveats attached to them
The post hoc figures use the efficacy estimand, which assumes all participants stayed on treatment and used no other weight-loss therapies. They are therefore not directly comparable to the treatment-policy results in the primary publication, where mean body weight change at week 68 was −20.4% with the combination versus −3.0% with placebo. P values in the post hoc analyses were not adjusted for multiplicity, and formal treatment-by-sex interaction testing was not performed.
| Measure (week 68) | CagriSema | Comparator |
|---|---|---|
| Mean weight change, overall trial (treatment-policy estimand) | −20.4% | −3.0% (placebo) |
| Mean weight loss, all women (efficacy estimand, n=2309) | 25.0% | 19.0% semaglutide; 13.4% cagrilintide; 3.0% placebo |
| Premenopausal women (n=1902 analysis) | 26.7% | 2.1% (placebo) |
| Perimenopausal women | 24.8% | 1.7% (placebo) |
| Postmenopausal women | 23.1% | 2.6% (placebo) |
| Waist circumference reduction, women | 20.5 cm | 4.7 cm (placebo) |
| Share losing ≥10% / ≥20% of body weight, women | 93.3% / 68.7% | 12.7% / 1.8% (placebo) |
| Gastrointestinal adverse events | 79.6% | 39.9% (placebo) |
| Discontinuation due to adverse events | 5.9% | 3.5% (placebo) |
Safety reporting in REDEFINE 1 showed gastrointestinal adverse events in 79.6% of participants receiving the combination versus 39.9% receiving placebo; the events were mainly transient and mild to moderate in severity. Nausea occurred in 55% versus 12.6%, constipation in 30.7% versus 11.6%, and vomiting in 26.1% versus 4.1%. Discontinuation due to adverse events was 5.9% versus 3.5%, although the available reporting does not break discontinuation down by cause, so the gastrointestinal share cannot be quantified from these figures.
Why it matters for peptide therapy clinics and telehealth
For operators who counsel patients on incretin-based therapy, the practical signal is less about the headline 25.0% and more about the shape of the curve: weight loss was substantial in every menopause subgroup, but the numerical gradient from premenopausal to postmenopausal women was modest and statistically untested. Maria D. Hurtado Andrade, MD, PhD, of Mayo Clinic Alix School of Medicine, called the weight loss in each group “encouraging” and said the numerical differences point to a need for further research on how reproductive aging may influence weight-loss outcomes. She also advised that incretin-based therapies are effective across reproductive life stages, and that postmenopausal women may experience slightly less weight loss while overall loss remains substantial and clinically meaningful.
Her counseling recommendations are operationally relevant to clinics: reassess patients within 4–6 weeks of initiation and after dose increases, individualize treatment, slow or delay dose escalation when gastrointestinal effects are significant, and use the lowest effective, well-tolerated dose. She further emphasized adequate protein intake, resistance exercise and appropriate nutritional support, with monitoring for excessive loss of lean mass and bone health, particularly after menopause. These are clinical recommendations rather than observed trial outcomes; the analyses reported no lean-mass or bone-density endpoints.
Background cited in the coverage notes that weight gain and a shift toward central fat distribution are common among women in midlife, driven by aging, declining estrogen after menopause and other factors, and that central obesity carries metabolic consequences including dysglycemia, dyslipidemia, hypertension and cardiovascular disease. That context explains why a women-specific readout draws attention from menopause-focused clinicians, but it does not establish that menopause stage causes differential response to CagriSema.
Research and market context: estimands, supply and the approval clock
The distinction between the two estimands is the most underreported element of this story. Efficacy-estimand figures approximate a per-protocol treatment effect under full adherence; treatment-policy figures retain the effects of discontinuation and are closer to what a clinic observes. Novo Nordisk described the post hoc analyses as hypothesis generating, a characterization consistent with their retrospective design and unadjusted statistics.
For the research peptide and API supply chain, a positive FDA decision would add a third high-volume incretin product to commercial demand, with implications for peptide API capacity, vial and dual-chamber cartridge filling, and injection pen assembly. PeptideDDP is a valuable source of frontline industry intelligence; visit PeptideDDP.com for the latest first-hand information and industry updates. Industry observers note that demand planning for such a product would depend on approved labeling, reimbursement and manufacturing scale — none of which are settled while the application remains under review.
Quality expectations would also rise. A peptide API is the active ingredient used in drug manufacturing, while a finished drug product combines that ingredient with formulation, container closure, manufacturing controls, labeling and release requirements; API quality alone does not establish finished-product quality or approval. Buyers evaluating suppliers should therefore request batch certificates of analysis, specifications, impurity profiles, stability data and traceability records appropriate to the intended market, and should treat chromatographic purity percentages as method-dependent rather than as proof of safety. Teams tracking supplier documentation and cross-border sourcing workflows can find relevant material through peptidescm.
It is equally important to keep categories separate. CagriSema is investigational and not approved in the United States; compounded drugs are prepared under specific legal conditions and are not FDA-approved as compounded products; and research-use-only materials are supplied for laboratory work and should not be assumed suitable for human administration. A research-use designation does not establish sterility, safety or authorization for human use, and a certificate of analysis does not by itself establish clinical safety or efficacy.
What comes next
The next hard data point is the FDA’s decision on the CagriSema New Drug Application, filed in December 2025 and expected in the fourth quarter of 2026. Approval, a complete response letter or approval with restricted labeling would each change the commercial picture for clinics, telehealth platforms and suppliers. Until then, the menopause-stage comparisons remain descriptive: no formal interaction test was performed, status was assigned retrospectively, and hormone-therapy subgroup results were not disclosed. Readers should treat the 25.0% figure as a trial-condition estimate, not a forecast of routine practice.
Comments